Skip to main content
. 2020 Dec 18;21(24):9660. doi: 10.3390/ijms21249660

Figure 2.

Figure 2

Treatment with ranolazine results in changes in immune check point proteins (ICP) and macrophages in the tumors. Tumors of treated mice (Figure 1C, 100 mg/kg) were collagenase-treated and used for flow analysis of ICP surface markers. (A,B) Mean fluorescence intensity (MFI) of PD1, Tim3, and Lag3 markers in exhausted CD4 (A) or CD8 (B) T-cells from treated tumors with 100 mg/kg ranolazine (vehicle, n = 9; rano n = 10), Mann–Whitney test; * p < 0.05. (C) Percentage of tumor macrophages in tumors treated with 100 mg/kg ranolazine; t-test; * p = 0.03. (D,E): Percentage (D) or MFI (E) of blood myeloid monocytes expressing PDL1 ligand in ranolazine-treated mice. Mann–Whitney test; ** p = 0.01. i-mono = inflammatory monocyte (likely immune suppressive); ss-mono = steady state monocytes.